Therapeutic process for treating panic disorders in humans comprising, the systemic administration of a 6-phenyl-8-chloro-4H-s-triazolo[4,3-a][1,4]benzodiazepine including the N-oxides and pharmacologically acceptable acid addition salts thereof in combination with a pharmaceutical carrier.

Use of .gamma.-linolenic acid and related materials alone or with zinc or .beta.-lactam antibiotics to treat skin disorders.

At least one barbiturate or one of its pharmaceutically acceptable salts is combined with cinnarizine or flunarizine or one of their pharmaceutically acceptable salts to provide a hypnotic requiring lower dosages of barbiturates to produce the same effect as the barbiturate alone.

Therapeutic process for treating panic disorders in humans comprising, the systemic administration of a 1-methyl-6-phenyl-8-chloro-4H-s-triazolo[4,3-a][1,4]benzodiazepine including the N-oxides and pharmacologically acceptable acid addition salts thereof in combination with a pharmaceutical carrier.

Therapeutic process for treating panic disorders in humans comprising the systemic administration of a 8-chloro-1-R-oxymethyl-6-phenyl-4H-s-triazolo[4,3-a][1,4]benzodiazepine of the formula ##STR1## wherein R is hydrogen, alkyl of from 1 to 3 carbon atoms, inclusive, ##STR2## wherein n is 0 to 16, inclusive, and m is 1 to 16 inclusive, including the N-oxides, esters, and pharmacologically acceptable acid addition salts thereof in combination with a pharmaceutical carrier.

Metal containing compounds have been found which increase bone growth, decrease hydroxyapatite solubility, increase the size and/or the perfection of hydroxyapatite crystals in bone, and increase the tensile strength of bone. These compounds, when administered to patients who are suffering from diseases characterized by bone resorption impede the flow of bone calcium into the blood, and encourage the growth of new, normal bone tissue.

Sleep disorders in mammals, such as insomnia and narcolepsy, are treated by administering an effective amount of ethyl 4-acetoxybutanoate, or a closely related homolog thereof.

A method of treating skin disorders comprises the step of applying thereto a composition wherein the main active ingredient comprises dimethyl isosorbide. It has been found that dimethyl isosorbide has a dermal penetrating action which can effectively carry it to the source of a skin disorder and that it has antifungal, antiviral and antibacterial effects which make it effective in the treatment of a wide range of skin disorders.

An agent and method for treating vasomotor disorders, particularly migraine and menstrual pain is provided wherein the method comprises administering to said patient, intravenously or orally, an effective dose of the agent according to the invention, Vitamin B.sub.6. The effective dose of vitamin B.sub.6 is at least about 100 mg., preferably at least about 300 mg. and most preferably at least about 400 mg. Vitamin B.sub.2 may also be administered for particularly effective results.

Metal-containing compounds have been found to decrease calcium resorption from bone. These compounds, when administered to patients who are suffering from diseases characterized by accelerated bone resorption, impede the flow of bone calcium into the blood and increase the calcium content of bone tissue.